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Abstract: Efficient catalysts for selective oxidation of C–H bonds using atmospheric oxygen are highly desirable 
to decrease the economic and environmental costs associated with conventional oxidation processes. We have 
used methods of directed evolution to generate variants of bacterial cytochrome P450 BM3 that catalyze hy-
droxylation and epoxidation of a wide range of nonnative substrates. This fatty acid hydroxylase was converted 
to a propane monooxygenase (PMO) capable of hydroxylating propane at rates comparable to that of BM3 on 
its natural substrates. Variants along the PMO evolutionary lineage showed broadened substrate scope; these 
became the starting points for evolution of a wide array of enzymes that can hydroxylate and derivatize organic 
scaffolds. This work demonstrates how a single member of enzyme family is readily converted by evolution into 
a whole family of catalysts for organic synthesis. 
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Simple reduced hydrocarbons obtained 
from petroleum feedstocks are used to 
produce over 90% of the world’s synthetic 
organic chemicals, including pharmaceuti-
cals, agrochemicals, and bulk commodity 
products.[1] This process begins with the ox-
idation of hydrocarbons to install functional 
groups that enable subsequent synthetic ma-
nipulations. While a variety of oxidants are 
currently used in these transformations on a 
massive scale, many provide only moderate 
yields or selectivities and produce environ-
mentally hazardous by-products. Further-
more, these methods are not applicable for 
the synthesis of fine chemicals and advanced 
intermediates with more complex structures 
and sensitive functional groups; extensive 
effort is required to manipulate the oxida-
tion state of these molecules throughout 
their preparation.[2] There is great interest 
therefore in developing catalysts capable of 
selective hydrocarbon oxidation under mild 
conditions using oxygen as the terminal 
oxidant.[3]
The advantages of such reactions have 
not been overlooked in nature, and diverse 
enzymatic solutions to this challenge en-
able organisms to utilize hydrocarbons 
and other hydrophobic substrates in meta-
bolic processes.[4] The cytochrome P450 
monooxygenase superfamily is a remark-
able example of how nature can generate a 
whole spectrum of catalysts from one com-
mon framework: more than 7,000 P450 
sequences identified from all kingdoms of 
life catalyze the oxidation of a huge vari-
ety of organic compounds. Each of these 
enzymes harbors a cysteine-bound heme 
cofactor responsible for this activity,[5] but 
the cytochrome P450 BM3 from Bacillus 
megaterium (BM3) possesses a number of 
features that make it particularly attractive 
for applications in chemical synthesis.[6] 
BM3 is one of only a handful of known 
P450s in which the heme domain and the 
diflavin reductase domains (FMN and 
FAD) required for generation of the active 
oxidant are fused in a single polypeptide 
chain.[6] Thus, BM3 is soluble, readily 
overexpressed in a variety of heterologous 
hosts, and requires only atmospheric oxy-
gen and a supply of nicotinamide adenine 
dinucleotide phosphate (NADPH) for hy-
droxylation activity.[7] The substrates of 
BM3, however, are largely limited to C12–
C18 fatty acids, which it hydroxylates at 
subterminal positions at rates of thousands 
of turnovers per minute, making it one of 
the most active hydroxylases known.[8]
Given the engineering-friendly prop-
erties of BM3 and the potential utility 
of C–H bond hydroxylation, we set out 
about ten years ago to explore and expand 
the substrate scope of this enzyme with 
the goal of creating efficient enzyme and 
whole-cell catalysts for a variety of oxida-
tive transformations. Extensive effort has 
been devoted by the research community 
to rational mutagenesis of P450 enzymes 
to probe the roles of various residues on 
substrate binding and catalysis.[9] Guided 
by numerous crystal structures of sub-
strate-bound and unbound P450s, these 
studies demonstrated that modification of 
properties was possible but time consum-
ing, complicated by complex interactions 
between structure and catalysis, and lim-
ited to modest modifications of properties. 
Inspired by the engineering approach that 
generated the impressive array of P450s 
in nature, we have instead used directed 
evolution, iterative rounds of mutagenesis 
and functional screening, to generate new 
BM3-based catalysts.[10]
One of our earliest goals was to engineer 
BM3 to hydroxylate linear alkanes, includ-
ing the short chain gaseous alkanes found 
in natural gas. Such a catalyst could enable 
bioconversion of natural gas to more con-
venient liquid alcohols for transportation or 
direct application as fuel, which has been a 
longstanding goal in catalysis with signifi-
cant economic and environmental impli-
cations.[1] While wild type BM3 has only 
weak activity on long-chain alkanes (and no 
measurable activity on short alkanes),[8] we 
hypothesized that mutants of this enzyme 
displaying enhanced alkane activity might 
acquire measurable ability to hydroxylate 
slightly shorter alkanes. Further mutagen-
esis of active variants, with screening on 
progressively shorter-chained substrates, 
could ultimately generate enzymes active 
on the gaseous alkanes. Breaking down an 
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apparently difficult problem (obtaining ac-
tivity on very small substrates) into a series 
of smaller problems lowers the bar for each 
generation, and can even allow new activi-
ties to be acquired one mutation at a time. 
This dramatically decreases the screening 
requirement, such that beneficial muta-
tions can be found upon screening only a 
few thousand clones per generation versus 
the many millions required to find even 
two simultaneous mutations.
We initially investigated BM3 libraries 
generated by random mutagenesis of the 
heme domain.[11] Error-prone PCR reac-
tion mixtures were plated, single colonies 
were picked, and variants were expressed 
in 96-well plates. The cells were then lysed 
and BM3 mutants in the crude lysate were 
used directly for hydroxylation, which en-
abled rapid analysis of thousands of P450 
sequences using various high through-
put assays for alkane hydroxylation. The 
octane surrogate 1-nitro-4-(octyloxy)
benzene (NOB) was used in early experi-
ments (Scheme 1A).[12] Hydroxylation of 
this substrate at the oxygen-bound meth-
ylene generates an unstable hemi-acetal 
intermediate that decomposes to octanal 
and p-nitrophenol, which can be detected 
using a plate reader. Similarly, hydroxy-
lation of the propane surrogate dimeth-
ylether (DME) generates formaldehyde, 
which can be detected following reaction 
with Purpald (Scheme 1B).[13] Consump-
tion of NADPH in the presence of various 
substrates (octane, propane, etc.) was also 
used in order to ensure that activity on sur-
rogate substrates translated to the desired 
substrate (Scheme 1C).[14] Ultimately, ac-
tivity on alkanes was confirmed by GC 
analysis of the alcohol products.
Five generations of random mutagen-
esis, recombination of beneficial muta-
tions, and screening for activity on NOB 
or octane led to the creation of BM3 vari-
ant 139-3.[15] This enzyme contains eleven 
amino acid substitutions relative to BM3, 
only one of which is in the active site. 139-3 
was able to hydroxylate C8–C3 n-alkanes. 
Further rounds of random mutagenesis, re-
combination, and more focused active site 
engineering further optimized the activity 
of 139-3 for hydroxylation of short-chain 
alkanes, using DME and propane assays 
to assess the mutants.[16] Variant 35E11, 
with 17 mutations relative to BM3, dis-
played high activity on propane, and even 
provided modest conversion of ethane to 
ethanol.[16b]
BM3-catalyzed hydroxylation requires 
finely tuned conformational rearrange-
ments within and between the heme and 
reductase domains in order to efficiently 
couple hydroxylation to NADPH con-
sumption.[17] These processes are disrupted 
when mutations are introduced or nonna-
tive substrates are utilized. Random muta-
genesis also decreases the thermostability 
of enzymes, which shortens catalyst life-
times, but more importantly limits further 
evolution.[18] These issues were addressed 
using a domain-based approach, in which 
the heme, FMN, and FAD domains of 
35E11 were evolved individually in the 
context of the holoenzyme and combined 
in a final step.[19] Optimization of the heme 
domain involved the introduction of ther-
mostabilizing mutations, followed by ran-
dom mutagenesis, saturation mutagenesis 
of active site residues, and recombination 
of active variants. Random mutagenesis 
of the FMN and FAD domains revealed 
a number of beneficial mutations, and 
saturation mutagenesis of these sites pro-
vided further improvements. Finally, the 
optimized domains were fused to generate 
P450PMOR2 (PMO), which provided more 
than 45,000 turnovers on propane and 
produced 2- and 1-propanol in a 9:1 ratio 
(Fig. 1A). This enzyme displayed activity 
on propane comparable to that of BM3 on 
its natural substrates and 98.2% coupling 
of NADPH consumption to product hy-
droxylation.
Investigation of the substrate profiles 
for variants along the lineage for the evo-
lution of PMO revealed that the specificity 
of BM3 for hydroxylation of long chain 
alkanes was relaxed in intermediate vari-
ants (e.g. 139-3, 35E11) and ultimately 
respecified to propane in the case of PMO 
(Fig. 1B).[20] This result was notable be-
cause only positive selection had been 
Scheme 1. Screens used in evolution of BM3. (A) Hydroxylation of nitro-4-(octyloxy)benzene 
(NOB) generates a colored phenol,[12] (B) hydroxylation of dimethylether (DME) generates 
formaldehyde, which reacts with Purpald to generate a colored heterocycle,[13] and (C) substrate 
hydroxylation consumes NADPH.[14] Each of these can be monitored by visible or fluorescence 
spectroscopy using a plate reader.
Fig. 1. (A) Total turnovers for variants along the PMO lineage on propane and ethane. (B) Activity 
of variants along the PMO lineage on Cn (n = 1–10) alkanes demonstrated how directed evolution 
passed through less-specific intermediate catalysts before re-specializing in on propane.[20]
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Synthesis of these valuable compounds 
is highly challenging using conventional 
synthetic methods, and efficient methods 
for their preparation are sorely needed.[31] 
Screening the BM3 collections revealed a 
number of variants capable of selectively 
removing single methyl groups from uni-
formly protected sugar derivatives, and di-
rected evolution was used to improve both 
the regioselectivity and activity of these 
variants. The deprotected monosaccha-
rides were then converted to deoxy-sugars, 
fluorinated sugars, and even disaccharides 
(J. Lewis, unpublished results).
used throughout this process and indicated 
that negative selection pressure is not neces-
sarily required to obtain high specificity for 
a new substrate. In addition, the broad sub-
strate scope of the intermediate variants sug-
gested that hydroxylation of additional sub-
strates might be possible,[21] and we began to 
investigate the activity of these intermediate 
enzymes on a variety of small molecules. 
Initial experiments revealed that 139-3 
catalyzed the hydroxylation of a variety of 
aliphatic and aromatic substrates and the ep-
oxidation of olefins at rates and conversions 
far greater than BM3 (Scheme 2A).[22] The 
hydroxylation of 2-aryl acetic acid deriva-
tives by alkane intermediate variant 9-10A 
was also investigated (Scheme 2B).[23] 
These substrates present the enzymes a 
number of different reactive C–H bonds 
(aromatic, benzyl, and alkyl). Due to differ-
ences in the mechanisms of aromatic and 
alkyl hydroxylation and differences in bond 
strength between primary, secondary, and 
benzyl alkyl C–H bonds, regioselectivity 
in these reactions is difficult to predict.[24] 
However, 9-10A proved to be an efficient 
catalyst in this respect, and hydroxylation 
proceeded with high regio- and enantiose-
lectivity at the benzyl position of certain 
substrates.
To further explore the reactivities of 
enzymes lying along the PMO lineage as 
well as BM3 variants from recombination 
experiments,[25] we compiled a collection 
of ~120 variants to screen for activity on 
a variety of substrates of interest. In a col-
laboration with scientists from Eli Lilly, 
we were able to use the enzymes from 
this small collection, to prepare nearly all 
of the human metabolites and a number 
of novel hydroxylated derivatives for the 
drugs verapamil and astemizole (Fig. 2).[26] 
The ability to rapidly determine potential 
metabolites of drug candidates greatly fa-
cilitates pharmacological and toxicological 
evaluations of these molecules in preclini-
cal studies,[27] so the broad scope demon-
strated by these BM3 variants should be 
particularly useful. This panel of enzymes 
could also be used further upstream in drug 
development as a means to generate deriv-
atives of candidate structures. 
In a similar fashion, highly active vari-
ants were identified for the hydroxylation 
of a variety of small molecules (Scheme 
3).[20,28] While these simple, predominantly 
hydrocarbon substrates are often commer-
cially available, functionalized derivatives 
are difficult to obtain. Thus the ability to 
install functional handles in these struc-
tures is highly useful for organic synthe-
sis. Furthermore, these hydroxylated prod-
ucts could be subsequently fluorinated in 
a chemo-enzymatic process that greatly 
simplified the installation of fluorine into 
these structures at specific positions.[28] 
Because the regioselectivity of fluorina-
tion is imparted by the P450 enzymes, this 
process could be particularly useful for 
improving the metabolic stability of drug 
candidates, since human P450s would be 
expected to hydroxylate at least some of 
these same positions in vivo.[29]
As a final example of the utility of 
BM3 variants in chemical synthesis, we 
have engineered BM3 to regioselectively 
deprotect permethylated monosaccharides 
in a chemoenzymatic method for synthesis 
of monosaccharide derivatives commonly 
found in pharmaceuticals and other bio-
logically active molecules (Scheme 4).[30] 
Scheme 2. (A) 
Oxidation of various 
small hydrocarbons 
using 139-3 in the 
presence of NADPH. 
Maximum initial 
rates (nmol NADPH 
consumed/min/nmol 
P450) for 139-3 and 
(BM3) are shown.[22]  
(B) Hydroxylation of 
phenyl acetic acid 
derivatives using 
9-10A in the presence 
of NADPH.[23]
Fig. 2. Structures 
of (A) verapamil 
and (B) astemizole. 
Sites hydroxylated 
by BM3 variants 
are designated 
with arrows.[26] 
Hydroxylation of 
heteroatom-bonded 
alkyl groups resulted 
in heteroatom 
dealkylation. 
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Together, these results demonstrate 
the ability of directed evolution to gener-
ate useful catalysts for oxidation of a wide 
range of substrates. Creation of the PMO 
highlights the stunning levels of efficiency 
possible using this process. In addition, 
the broad substrate scope of variants along 
the PMO lineage as well as those obtained 
by recombination has enabled rapid hy-
droxylation and derivatization of common 
organic scaffolds that would be difficult 
to accomplish using standard chemical 
means. Specific transformations were eas-
ily improved by further directed evolu-
tion of variants possessing broad substrate 
scope. These examples demonstrate the 
remarkable ability of cytochrome P450 to 
adapt to new challenges, an ability we ex-
pect to continue to exploit in the production 
of catalysts useful in chemical synthesis.
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